PI3K

Drug Repositioning Identifies Six Drug Candidates for Systemic Autoimmune Diseases by Integrative Analyses of Transcriptomes from Scleroderma, Systemic Lupus Erythematosus, and Sjogren's Syndrome

0 views | Jan 18 2024

This study utilizing transcriptome data and bioinformatic analysis identified common gene signatures across systemic autoimmune diseases, leading to the discovery of six potential small molecule drug candidates through drug repositioning, shedding light on novel therapeutic avenues for these conditions. [Read the Full Post]

Preliminary In Vitro and In Vivo Insights of In Silico Candidate Repurposed Drugs for Alzheimer's Disease

12 views | Jan 15 2024

Your study on repurposed drugs for Alzheimer's disease highlights promising candidates like clomiphene citrate and Pik-90, signaling a step forward in bridging computational predictions with experimental validation. [Read the Full Post]

MTX-211 Inhibits GSH Synthesis through Keap1/NRF2/GCLM Axis and Exerts Antitumor Effects in Bladder Cancer

45 views | Jan 10 2024

MTX-211 demonstrates promising potential as a therapeutic agent for bladder cancer by inhibiting cell proliferation through the Keap1/NRF2/GCLM signaling pathway and depleting intracellular GSH levels. [Read the Full Post]

Quantitative Proteomics Characterization of the Effect and Mechanism of Trichostatin A on the Hippocampus of Type II Diabetic Mice

37 views | Jan 03 2024

The study demonstrates Trichostatin A's potential in improving cognitive function in diabetic encephalopathy by modulating key proteins and pathways, highlighting its promise as a therapeutic intervention and suggesting potential similar and ancillary drugs for treatment. [Read the Full Post]

Translating in vitro CFTR rescue into small molecule correctors for cystic fibrosis using the Library of Integrated Network-based Cellular Signatures drug discovery platform

40 views | Dec 29 2023

Research employing transcriptomic signatures from CF expression data and LINCS in silico screening identified XL147, among other compounds, as a promising candidate for partially restoring ΔF508-CFTR function, showing efficacy in primary CF airway epithelia and demonstrating potential for improved CF corrector therapies. [Read the Full Post]

Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study

21 views | Dec 15 2023

This controlled umbrella trial demonstrated the feasibility of IHC-based screening for druggable targets in HER2-negative advanced gastric cancer, with targeted agents in the biomarker group showing mixed efficacy, indicating the potential for early screening of novel therapies in specific subgroups. [Read the Full Post]

Glucose metabolic upregulation via phosphorylation of S6 ribosomal protein affects tumor progression in distal cholangiocarcinoma

67 views | Dec 13 2023

In summary, the study reveals that inhibiting phosphorylated S6 ribosomal protein, a marker of mTORC1 activity, suppresses glucose metabolism pathways and reduces cell proliferation, suggesting mTORC1 as a potential therapeutic target in distal cholangiocarcinoma. [Read the Full Post]

MLN4924 inhibits hedgehog signaling pathway and activates autophagy to alleviate mouse laser-induced choroidal neovascularization lesion

0 views | Dec 11 2023

MLN4924, a selective inhibitor of NEDD8-activating enzyme, mitigates neovascular age-related macular degeneration by inhibiting choroidal neovascularization through the upregulation of hedgehog pathway-regulated autophagy in choroidal endothelial cells under hypoxia conditions. [Read the Full Post]

Lipopolysaccharide-induced Trigeminal Ganglion Nerve Fiber Damage is Associated with Autophagy Inhibition

32 views | Dec 09 2023

**LPS-induced inhibition of autophagy leads to trigeminal ganglion neurite loss, highlighting a potential therapeutic target for corneal nerve damage.** [Read the Full Post]

Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study

34 views | Nov 11 2023

The combination of tenalisib and romidepsin showed promising efficacy with a 63.0% overall objective response rate in patients with relapsed/refractory T-cell lymphoma, along with a manageable safety profile, supporting its further development as a potential treatment option. [Read the Full Post]